Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Zosyn Inventory Allocation Program Likely To Last Through 2002

Executive Summary

Wyeth is suspending production of Pipracil (piperacillin) in order to increase supplies of the piperacillin/tazobactam combination agent Zosyn, the company said in a Feb. 27 letter to the trade

You may also be interested in...



Wyeth Allocates Prempro/Premarin Inventories; Stocking Too High, Firm Says

Wyeth has implemented temporary allocation caps on its conjugated estrogens product line in an effort to reduce inventories in the trade

Wyeth Allocates Prempro/Premarin Inventories; Stocking Too High, Firm Says

Wyeth has implemented temporary allocation caps on its conjugated estrogens product line in an effort to reduce inventories in the trade

Wyeth/Amgen Enbrel Adds 25,000 Patients In Q1; Prevnar Back Orders Cleared

Improved supply for Wyeth/Amgen's Enbrel is allowing for the first significant increase in the number of patients on the TNF inhibitor in more than a year

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel